- Pertinent Findings: Baseline tumor LS by SWE, before anti-PD-1 in combination with lenvatinib, is a convenient predictor of tumor progression in patients with advanced HCC through a retrospective analysis of two independent cohorts. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.